Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion type Assertion NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_head.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion evidence source_evidence_literature NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion SIO_000772 15948676 NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion wasDerivedFrom befree-20150227 NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion wasGeneratedBy ECO_0000203 NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.